447 filings
Page 9 of 23
6-K
m09r5uoec4it4 6o9
12 Aug 20
Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA
9:26am
424B3
nvya8
28 Jul 20
Prospectus supplement
4:18pm
EFFECT
qt24 52rsoa
28 Jul 20
Notice of effectiveness
12:15am
UPLOAD
jzzzk
24 Jul 20
Letter from SEC
12:00am
CORRESP
cu8o0c7ceq5mepr
24 Jul 20
Correspondence with SEC
12:00am
F-1
mlbkh7 tjrc1xr1y
17 Jul 20
Registration statement (foreign)
4:26pm
6-K
d0qyxidwyxilgu0os6
1 Jul 20
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
9:22am
6-K
cp7dg
1 Jul 20
Akari Therapeutics Announces Appointment of Chief Financial Officer
9:19am
6-K
5361q99500
1 Jun 20
This Document Is Important and Requires Your Immediate Attention
8:32am
6-K
eaunyg4x mm16wh9
29 May 20
Current report (foreign)
7:30am
6-K
jz5f xy2p
21 May 20
Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid
4:17pm
EFFECT
wyf5nmjtl75rmw zh
12 May 20
Notice of effectiveness
12:15am
6-K
wvaqv8y3m h9
1 May 20
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
8:32am
POS AM
5vtifx51 7vzqiqbm
27 Apr 20
Prospectus update (post-effective amendment)
4:14pm
EFFECT
jpv eqsk14tfcetvf98g
20 Apr 20
Notice of effectiveness
12:15am
424B3
j9psxwu gl000bg
17 Apr 20
Prospectus supplement
4:56pm
EFFECT
bytn4b2ec
17 Apr 20
Notice of effectiveness
12:15am
CORRESP
t45qyks5
15 Apr 20
Correspondence with SEC
12:00am
F-3/A
p35hgt
15 Apr 20
Shelf registration (foreign) (amended)
12:00am
POS AM
b9fc2ad
8 Apr 20
Prospectus update (post-effective amendment)
4:15pm